Milan Bustamante-Garrido
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Milan Bustamante-Garrido has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Alexander Marx
19 shared publicationsBo Li
19 shared publications- Bruce Moran
St Vincent’s University Hospital, D04 T6F4 Dublin, Ireland
19 shared publications - Katja Simon-Keller
Institute of Pathology, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany
19 shared publications - Niamh E. Buckley
School of Pharmacy, Queen’s University Belfast, Belfast, Northern Ireland
19 shared publications Nollaig Healy
19 shared publications
Latest Publications
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from PDLIM2 Is a Marker of Adhesion and β-Catenin Activity in Triple-Negative Breast Cancer
The PDLIM2 protein regulates stability of transcription factors including NF-κB and STATs in epithelial and hemopoietic cells. PDLIM2 is strongly expressed in certain cancer cell lines that exhibit an epithelial-to-mesenchymal phenotype, and its suppression is sufficient to reverse this phenotype. PDLIM2 supports the epithelial polarity of nontransformed breast cells, suggesting distinct roles in tumor suppression and oncogenesis. To better understand its overall function, we investigated PDLIM2 expression and activity in breast cancer. PDLIM2 protein was present in 60% of tumors diagnosed as triple-negative breast cancer (TNBC), and only 20% of other breast cancer subtypes. High PDLIM2 expression in TNBC was positively correlated with adhesion signaling and β-catenin activity. Interestingly, PDLIM2 was restricted to the cytoplasm/membrane of TNBC cells and excluded from the nucleus. In breast cell lines, PDLIM2 retention in the cytoplasm was controlled by cell adhesion, and translocation to the nucleus was stimulated by insulin-like growth factor-1 or TGFβ. Cytoplasmic PDLIM2 was associated with active β-catenin and ectopic expression of PDLIM2 was sufficient to increase β-catenin levels and its transcriptional activity in reporter assays. Suppression of PDLIM2 inhibited tumor growth in vivo, whereas overexpression of PDLIM2 disrupted growth in 3D cultures. These results suggest that PDLIM2 may serve as a predictive biomarker for a large subset of TNBC whose phenotype depends on adhesion-regulated β-catenin activity and which may be amenable to therapies that target these pathways.Significance:This study shows that PDLIM2 expression defines a subset of triple-negative breast cancer that may benefit from targeting the β-catenin and adhesion signaling pathways.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from PDLIM2 Is a Marker of Adhesion and β-Catenin Activity in Triple-Negative Breast Cancer
The PDLIM2 protein regulates stability of transcription factors including NF-κB and STATs in epithelial and hemopoietic cells. PDLIM2 is strongly expressed in certain cancer cell lines that exhibit an epithelial-to-mesenchymal phenotype, and its suppression is sufficient to reverse this phenotype. PDLIM2 supports the epithelial polarity of nontransformed breast cells, suggesting distinct roles in tumor suppression and oncogenesis. To better understand its overall function, we investigated PDLIM2 expression and activity in breast cancer. PDLIM2 protein was present in 60% of tumors diagnosed as triple-negative breast cancer (TNBC), and only 20% of other breast cancer subtypes. High PDLIM2 expression in TNBC was positively correlated with adhesion signaling and β-catenin activity. Interestingly, PDLIM2 was restricted to the cytoplasm/membrane of TNBC cells and excluded from the nucleus. In breast cell lines, PDLIM2 retention in the cytoplasm was controlled by cell adhesion, and translocation to the nucleus was stimulated by insulin-like growth factor-1 or TGFβ. Cytoplasmic PDLIM2 was associated with active β-catenin and ectopic expression of PDLIM2 was sufficient to increase β-catenin levels and its transcriptional activity in reporter assays. Suppression of PDLIM2 inhibited tumor growth in vivo, whereas overexpression of PDLIM2 disrupted growth in 3D cultures. These results suggest that PDLIM2 may serve as a predictive biomarker for a large subset of TNBC whose phenotype depends on adhesion-regulated β-catenin activity and which may be amenable to therapies that target these pathways.Significance:This study shows that PDLIM2 expression defines a subset of triple-negative breast cancer that may benefit from targeting the β-catenin and adhesion signaling pathways.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from PDLIM2 Is a Marker of Adhesion and β-Catenin Activity in Triple-Negative Breast Cancer
Related to Figures 5 and 6: Contains images of PDLIM2 immunocytochemistry staining of PDLIM2-negative TNBC cell lines not included in Figure 5 and additional analysis of TN Breast cells under adhesion versus suspension conditions. Protein expression and quantification of β-catenin phosphorylated on Ser675 are also shown. Immunofluorescence images of HA-PDLIM2 overexpressed in BT549 cells are included.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from PDLIM2 Is a Marker of Adhesion and β-Catenin Activity in Triple-Negative Breast Cancer
Related to Figures 5 and 6: Contains images of PDLIM2 immunocytochemistry staining of PDLIM2-negative TNBC cell lines not included in Figure 5 and additional analysis of TN Breast cells under adhesion versus suspension conditions. Protein expression and quantification of β-catenin phosphorylated on Ser675 are also shown. Immunofluorescence images of HA-PDLIM2 overexpressed in BT549 cells are included.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from PDLIM2 Is a Marker of Adhesion and β-Catenin Activity in Triple-Negative Breast Cancer
Related to Figure 6: Western blots and immunofluorescence images of PDLIM2 and b-catenin phospho-Ser675 expression and localization in BT549 cells overexpressing HA-PDLIM2 are included. Graph depicting measurements of cell migration in HA-PDLIM2-expressing BT549 is shown. The effects of suppression of PDLIM2 on b-catenin and b1-integrin levels in HCC1806 and MDA-MB-231-LUC2 are shown. Further analyses of effects of loss of adhesion and also, serum starvation, on PDLIM2 and active b-catenin subcellular localization in TN Breast cell lines are also shown.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from PDLIM2 Is a Marker of Adhesion and β-Catenin Activity in Triple-Negative Breast Cancer
Related to Figure 6: Western blots and immunofluorescence images of PDLIM2 and b-catenin phospho-Ser675 expression and localization in BT549 cells overexpressing HA-PDLIM2 are included. Graph depicting measurements of cell migration in HA-PDLIM2-expressing BT549 is shown. The effects of suppression of PDLIM2 on b-catenin and b1-integrin levels in HCC1806 and MDA-MB-231-LUC2 are shown. Further analyses of effects of loss of adhesion and also, serum starvation, on PDLIM2 and active b-catenin subcellular localization in TN Breast cell lines are also shown.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from PDLIM2 Is a Marker of Adhesion and β-Catenin Activity in Triple-Negative Breast Cancer
Related to Figures 2 and 3: Shows counts of distribution of IHC scores of PDLIM2 staining in RATHER cohort based on TNBC subtype. Includes analysis of TNBC subtypes of tissues in the RATHER cohorts in relation to PDLIM2 expression, a Kaplan Meier plot of breast cancer specific survival in relation to TNBC subtype, and correlation plot of PDLIM2 mRNA and protein expression in the RATHER cohorts. Examples of nuclear PDLIM2 expression in stromal/infiltrating cells are also shown.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from PDLIM2 Is a Marker of Adhesion and β-Catenin Activity in Triple-Negative Breast Cancer
Related to Figures 2 and 3: Shows counts of distribution of IHC scores of PDLIM2 staining in RATHER cohort based on TNBC subtype. Includes analysis of TNBC subtypes of tissues in the RATHER cohorts in relation to PDLIM2 expression, a Kaplan Meier plot of breast cancer specific survival in relation to TNBC subtype, and correlation plot of PDLIM2 mRNA and protein expression in the RATHER cohorts. Examples of nuclear PDLIM2 expression in stromal/infiltrating cells are also shown.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from PDLIM2 Is a Marker of Adhesion and β-Catenin Activity in Triple-Negative Breast Cancer
Related to Figure 4: Includes TNBC subtype classification of the cell lines used in this study and additional analyses of expression of PDLIM2 and epithelial/mesenchymal markers. A graph illustrates PDLIM2 RNASeq and protein expression in the cell lines. Expression of b1 integrin, Phospho-EGFR, Phospho-IGF-1R and Phospho c-Met in TN Breast cell lines are also shown.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from PDLIM2 Is a Marker of Adhesion and β-Catenin Activity in Triple-Negative Breast Cancer
Related to Figure 4: Includes TNBC subtype classification of the cell lines used in this study and additional analyses of expression of PDLIM2 and epithelial/mesenchymal markers. A graph illustrates PDLIM2 RNASeq and protein expression in the cell lines. Expression of b1 integrin, Phospho-EGFR, Phospho-IGF-1R and Phospho c-Met in TN Breast cell lines are also shown.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from PDLIM2 Is a Marker of Adhesion and β-Catenin Activity in Triple-Negative Breast Cancer
Supplementary Table I (RPPA) and Table II (Gene expression data).
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from PDLIM2 Is a Marker of Adhesion and β-Catenin Activity in Triple-Negative Breast Cancer
Supplementary Table I (RPPA) and Table II (Gene expression data).
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from PDLIM2 Is a Marker of Adhesion and β-Catenin Activity in Triple-Negative Breast Cancer
Related to Figure 2: Shows data for distribution of IHC scores of PDLIM2 staining in TNBC tissues and examples of PDLIM2 IHC images of normal tissue. Includes Kaplan Meier curves and clinicopathological analysis of RATHER cohorts in relation to PDLIM2 expression.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from PDLIM2 Is a Marker of Adhesion and β-Catenin Activity in Triple-Negative Breast Cancer
Related to Figure 2: Shows data for distribution of IHC scores of PDLIM2 staining in TNBC tissues and examples of PDLIM2 IHC images of normal tissue. Includes Kaplan Meier curves and clinicopathological analysis of RATHER cohorts in relation to PDLIM2 expression.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from PDLIM2 Is a Marker of Adhesion and β-Catenin Activity in Triple-Negative Breast Cancer
Related to Figure 1: Includes additional images of immunohistochemical staining and scores of PDLIM2 expression in tumor and stroma of Breast Cancer TMA samples.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from PDLIM2 Is a Marker of Adhesion and β-Catenin Activity in Triple-Negative Breast Cancer
Related to Figure 1: Includes additional images of immunohistochemical staining and scores of PDLIM2 expression in tumor and stroma of Breast Cancer TMA samples.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from PDLIM2 Is a Marker of Adhesion and β-Catenin Activity in Triple-Negative Breast Cancer
Supplementary Table I (RPPA) and Table II (Gene expression data).
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from PDLIM2 Is a Marker of Adhesion and β-Catenin Activity in Triple-Negative Breast Cancer
Supplementary Table I (RPPA) and Table II (Gene expression data).